Immunometabolism therapies could offer a way to reverse inflammation and cure diseases, according to Neil Weir, CEO of Sitryx. This emerging field in therapeutics looks at the overlap between metabolic pathways and the immune cell synthesis process, allowing very specific targeted therapies which influence the immune system without causing dangerous side effects. Sitryx has three drugs in various stages of development for a variety of autoimmune diseases, while Texas-based ImmunoMet is likewise developing lixumistat, which has various uses including in pancreatic cancer trials.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
